| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 2006年11月20日，香港药本召开董事会，通过决议设立药石有限。 2015年12月1日通过的创立大会决议，以经天衡会计师事务所（特殊普通合伙）审计的截至2015年10月31日的净资产人民币143,004,384.40元为基数，按照2.86008769：1的比例折合成股本5,000万元，药石有限整体变更为股份公司。 2015年12月16日，公司在南京市工商行政管理局高新技术产业开发区分局办理工商变更，并取得统一社会信用代码为913201917937313394的《营业执照》。 公司是一家生物医药技术领域的高新技术企业，公司凭借自身在化学合成方面的技术优势，并结合对药物研发的深刻理解，在小分子药物研发领域提供药物分子砌块产品和相关技术服务。发行人主营业务包括：药物分子砌块的设计、合成和销售；关键中间体的工艺开发、中试、商业化生产和销售；药物分子砌块的研发和工艺生产相关的技术服务。 | ||||||||||||||||||||||||
| Main Business | 药物分子砌块的设计、合成和销售；关键中间体的工艺开发、中试、商业化生产和销售；药物分子砌块的研发和工艺生产相关的技术服务。 | ||||||||||||||||||||||||
| Legal Representative | 杨民民 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 吴奕斐 | ||||||||||||||||||||||||
| Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
| Auditors | 中天运会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 025-86918230 | ||||||||||||||||||||||||
| Fax No | 025-86918262 | ||||||||||||||||||||||||
| Website | www.pharmablock.com | ||||||||||||||||||||||||
| PB-Securities@PharmaBlock.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/11/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.990 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.310 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 13.551 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 6.070B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |